CN101453982B - Two-piece, internal-channel osmotic delivery system flow modulator - Google Patents

Two-piece, internal-channel osmotic delivery system flow modulator Download PDF

Info

Publication number
CN101453982B
CN101453982B CN2007800187567A CN200780018756A CN101453982B CN 101453982 B CN101453982 B CN 101453982B CN 2007800187567 A CN2007800187567 A CN 2007800187567A CN 200780018756 A CN200780018756 A CN 200780018756A CN 101453982 B CN101453982 B CN 101453982B
Authority
CN
China
Prior art keywords
delivery system
osmotic delivery
container
inner core
shell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2007800187567A
Other languages
Chinese (zh)
Other versions
CN101453982A (en
Inventor
S·D·劳滕巴赫
P·E·德拉瑟纳
P·C·赞莫拉
M·A·德斯贾丁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intarcia Therapeutics Inc
Original Assignee
Intarcia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intarcia Therapeutics Inc filed Critical Intarcia Therapeutics Inc
Publication of CN101453982A publication Critical patent/CN101453982A/en
Application granted granted Critical
Publication of CN101453982B publication Critical patent/CN101453982B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142Pressure infusion, e.g. using pumps
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T137/00Fluid handling
    • Y10T137/0318Processes
    • Y10T137/0402Cleaning, repairing, or assembling
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T29/00Metal working
    • Y10T29/49Method of mechanical manufacture
    • Y10T29/49229Prime mover or fluid pump making
    • Y10T29/49236Fluid pump or compressor making
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T29/00Metal working
    • Y10T29/49Method of mechanical manufacture
    • Y10T29/494Fluidic or fluid actuated device making

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Materials For Medical Uses (AREA)
  • Amplifiers (AREA)
  • Stabilization Of Oscillater, Synchronisation, Frequency Synthesizers (AREA)
  • Prostheses (AREA)
  • External Artificial Organs (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)

Abstract

An osmotic delivery system flow modulator includes an outer shell constructed and arranged for positioning in an opening of a reservoir of an osmotic delivery system, an inner core inserted in the outer shell, and a fluid channel having a spiral shape defined between the outer shell and the inner core. The fluid channel is adapted for delivery of an active agent formulation from the reservoir of the osmotic delivery system.

Description

Two-piece, internal-channel osmotic delivery system flow modulator
The cross reference of related application
The application requires the priority of the U.S. Provisional Application 60/809,451 on May 30th, 2006, and the content of described application is merged in this paper as a reference.
Background of invention
Relate generally to of the present invention is used for continuing at fluid environment the osmotic delivery system of active agent delivery.More specifically, the present invention relates to be used at the flow conditioner of fluid environment from the osmotic delivery system active agent delivery.
Fig. 1 has illustrated the osmotic delivery system 40 of prior art, and is described as people's such as Peterson United States Patent (USP) 6,524,305.Described delivery system 40 comprises the housing 42 that holds penetrating agent 47 and activating agent 44.Resolution element 46 forms spacer between penetrating agent 47 and activating agent 44.Semi-permeable plug 48 is inserted in first opening 45 of housing 42.Semi-permeable plug 48 optionally allows fluid to enter the inside of housing 42.Flow conditioner 20 is inserted in second opening 39 of housing 42.Flow conditioner 20 allows activating agent 44 to leave the inside of housing 42, and controls the inside of fluid back-diffusion to housing 42.When osmotic delivery system 40 is placed in the fluid environment, enter housing 42 and infiltrate penetrating agent 47 by semipermeable plug 48 from the fluid of housing 42 outsides, cause that penetrating agent 47 expands.Penetrating agent 47 moves resolution element 46 when expanding, and causes that activating agent 44 is delivered to applied environment by flow conditioner 20.
In the osmotic delivery system 40 of the prior art shown in Fig. 1, the outer surface of flow conditioner 20 comprises spiral helicine delivery path 32, activating agent 44 by described delivery path 32 from the internal circulation of housing 42 to the outside.Form the inner surface 43 of screw thread (thread) the 36 butt housings 42 of helical delivery path 32, make activating agent 44 by helical delivery path 32 time, contact the inner surface 43 of housing 42.Spacing, distance, cross-sectional area and shape to helical delivery path 32 are selected, and make that from the fluid environment to the housing back-diffusion in 42 minimizes.Filler opening 22 and steam vent 24 are provided in flow conditioner 20.When this osmotic delivery system 40 of assembling, at first flow conditioner 20 is inserted in the housing 42.By filler opening 22 activating agent 44 is expelled in the housing 42 then, and the gas in the housing 42 flows out by steam vent 24., end cap 26 be inserted in hole 22,24, make and only sending of activating agent 44 taken place by helical delivery path 32 thereafter.
From foregoing as seen, still wish the reliability and the flow adjustment ability that in osmotic delivery system, provide other.
Summary of the invention
In one aspect, the present invention relates to the osmotic delivery system flow conditioner, it comprises the shell that is configured and arranges the vessel port that is used for being positioned at osmotic delivery system, be inserted into the inner core in the shell, and the helical form flow channel that between described shell and inner core, limits, described flow channel is suitable for the container delivery of active agent formulation from osmotic delivery system.
In one aspect of the method, the present invention relates to osmotic delivery system, it comprises container; Be arranged on first end of described container, the mobile semipermeable plug that is used for optionally allowing to enter container; Be arranged on the flow conditioner of second end of described container, described flow conditioner comprises and is suitable for being delivered to internal helicoid passage in the fluid environment that described osmotic delivery system works therein with being included in active agent formulation in the container.
In a further aspect, the present invention relates to be used for the implantable delivery system of active agent formulation, it comprises the container of being made by non-permeable material, first Room that comprises the osmotic engine material in described container, second Room that comprises active agent formulation in described container, be arranged on container first terminal and the first Room adjacency semipermeable plug and be arranged on second Room of container and the aforesaid flow conditioner of the second Room adjacency.
From the following description book and the apparent other features and advantages of the present invention of claim subsequently.
Description of drawings
Description of drawings as described below typical embodiment of the present invention, and it should be thought of as and limit the scope of the invention, because the present invention can allow other same effectively embodiment.Not necessarily pro rata in the accompanying drawing, and for clarity and conciseness, some feature among the figure and some view may amplify on ratio or schematically.
Fig. 1 describes the cutaway view of prior art osmotic delivery system.
Fig. 2 A describes the phantom of flow conditioner, and described flow conditioner has inner core that is inserted in the shell and the internal helicoid flow channel that is formed in the inner core.
Fig. 2 B describes the phantom of flow conditioner, and described flow conditioner has inner core that is inserted in the shell and the internal helicoid flow channel that is formed in the shell.
Fig. 2 C describes the phantom of flow conditioner, and described flow conditioner has inner core that is inserted in the shell and the internal helicoid flow channel that is formed in inner core and the shell.
Fig. 2 D describes the phantom of flow conditioner, and described flow conditioner has inner core and the mobile insert that is inserted in the shell, and described mobile insert comprises the internal helicoid flow channel that is inserted between inner core and the shell.
Fig. 2 E describes the phantom of flow conditioner, and described flow conditioner has the inner core that is inserted in the shell and the composition surface on inner core and the shell, is used to prevent that inner core from discharging from shell.
Fig. 3 describes the cutaway view of the osmotic delivery system of the flow conditioner with Fig. 2 A.
The external accumulative total that Fig. 4 describes the activating agent that the osmotic delivery system of using Fig. 3 obtains discharges.
Detailed Description Of The Invention
With reference now to writing up the present invention as the several preferred embodiments that illustrate in the accompanying drawing.When describing preferred embodiment, set forth many details and fully understood of the present invention so that provide.Yet those skilled in the art can put into practice the present invention under the situation of not using some or all these details.In other situation, well-known features and/or processing step are not described in detail, so that unnecessarily make the present invention unclear.In addition, similar or identical reference number is used to represent shared or similar elements.
Fig. 2 A describes the phantom be used for from the flow conditioner 200 of the container delivery of active agent formulation of osmotic delivery system to 2E.With reference to figure 2A, flow conditioner 200 has the entrance side 201 of the active agent formulation in the container that is exposed to osmotic delivery system and is exposed to the outlet side 203 of the fluid environment that osmotic delivery system works therein.Typically, fluid environment is a liquid phase environment, that is to say, described fluid comprises water.Flow conditioner 200 comprises shell 202 and is inserted in the shell 202 and is generally columniform inner core 204.Between shell 202 and inner core 204, there is spiral helicine flow channel 206 to extend to outlet side 203 from the entrance side of flow conditioner 200.All of flow channel 206 or significant part can be helical form.Flow channel 206 is in flow conditioner 200 inside.Therefore, flow conditioner 200 forms barrier between the container of active agent formulation by flow channel 206 and osmotic delivery system.
In Fig. 2 A-2C, the outer surface 210 of inner core 204 cooperates with the inner surface 212 of shell 202.Flow channel 206 can be formed in the outer surface 210 of inner core 204, and shown in Fig. 2 A, perhaps flow channel 206 is formed in the inner surface 212 of shell 202, shown in Fig. 2 B.Perhaps, shown in Fig. 2 C, fluid passage 206 can comprise the first flow channel 206a in the outer surface 210 that is formed on inner core 204 and be formed on the second flow channel 206b in the inner surface 212 of shell 202, and wherein the first flow channel 206a and the second flow channel 206b are against each other or be communicated with.All of each flow channel 206a, 206b or significant part are helical form.Perhaps, shown in Fig. 2 D, the insert 214 that flows can be arranged between the inner surface 212 of the outer surface 210 of inner core 204 and shell 202, and the insert 214 that wherein flows provides flow channel 206.The insert 214 that flows can be for example coil pipe, and the distance between each circle of pipe plays the effect of flow channel 206.Perhaps, the insert 214 that flows can be the cylinder or the sleeve pipe of the hollow that wherein is formed with helical groove, and wherein helical groove plays the effect of flow channel 206.Flow channel 206 can have any required cross section, and the example comprises annular or D shape.The flow channel of in Fig. 2 A-2E, having represented D shape.The length of flow channel 206 depends on the structure of osmotic delivery system and required rate of release.Typically, ((spiral) length of flow channel 206 is 10 to 50mm.Typically, the effective cross-section diameter of flow channel 206 is 0.1 to 0.5mm.These scopes provide as an example, rather than are used to limit the present invention, except as otherwise noted.
With reference to figure 2A-2D, the maximum outside diameter of inner core 204 and the maximum inner diameter of shell 202 are selected, make between the inner surface 212 of the outer surface 210 of inner core 204 and shell 202, to form interference fit or sealing.This interference fit or sealing restriction preparation flow in the passage 206.This interference fit or sealing are enough to prevent that inner core 204 and/or mobile insert 214 are from shell 202 discharges.On the other hand, in Fig. 2 A-2C, the mating part on the surface 210,212 of inner core 204 and shell 202 can for example comprise respectively and be threaded, bonding connection, feature such as be welded to connect, so that in addition with respect to the fixing inner core 204 of shell 202.In Fig. 2 D, can between the part of interior and outer surface 214a, the 214b of the mobile insert 214 that cooperates with the surface 210,212 of inner core 204 and shell 202 respectively, form similar connection features.Fig. 2 E discloses the alternative approach that is used to prevent that inner core 204 from discharging from shell 202, and it is included in the outside shoulder 216 on the outer surface 210 of inner core 204, the inboard shoulder 218 butt/engagements on the inner surface 212 of itself and shell 202.Outlet side 203 discharges of inner core 204 have been prevented like this by flow conditioner 200.Butt/the mating surface of shoulder 216,218 can be flat or can be and phases down, as shown in Fig. 2 E.
Using butt/engagement shoulder 216,218 to prevent that inner core 204 is discharged to the fluid environment that osmotic delivery system works therein from shell 202 goes among the arbitrary embodiment shown in Fig. 2 A-2D.In addition, any feature of embodiment shown in Fig. 2 A-2E can be exchanged and combination, to produce the alternate embodiment of flow conditioner 200.For example, in Fig. 2 E, spiral helicine passage also can be arranged in the inner surface 212 of shell 202 as shown in Fig. 2 C.Perhaps, in Fig. 2 D, spiral helicine passage also can be arranged in the inner surface 212 of shell 202 and/or the outer surface 210 of inner core 204, respectively described in Fig. 2 A and 2B, wherein the flow channel 206 in the passage in shell 202 and/or the inner core 204 and the mobile insert 214 in abutting connection with or be communicated with.
With reference to figure 2A-2E, shell 202, inner core 204 and mobile insert 214 are preferably formed by inertia and biocompatible material.The example of inert biocompatible material includes but not limited to non-reactive polymer and metal for example titanium, rustless steel, platinum and their alloy and cochrome.When can be used for wherein wishing in active agent formulation being delivered to the fluid environment that osmotic delivery system works therein, non-reactive polymer avoids the interactional situation between active agent formulation and the metal material.The example of the non-reactive polymer that is fit to includes but not limited to PAEK for example polyether-ether-ketone and polyaryletheretherketone, ultra-high molecular weight polyethylene, fluorizated ethylene-propylene, polymethylpentene and liquid crystal polymer.Preferably, at least following surface is not by making or scribble described material to the material that active agent formulation has an illeffects, and described surface is included in the surface of the shell 202, inner core 204 and the mobile insert 214 that are exposed to active agent formulation when active agent formulation flows through flow channel 206.In a preferred embodiment, above-mentioned surface is made by inert and biocompatible nonmetallic materials.This nonmetallic materials can be non-reactive polymer, and the example provides above-mentioned.
Can select length, shape of cross section and the circulating area of flow channel 206, make the average linear velocity of active agent formulation by flow channel 206 than material because diffusion or infiltration are higher from the linear average linear velocity that inwardly flows into of fluid environment that osmotic delivery system works therein.Can have decay like this or relax the effect of back-diffusion,, then may pollute the active agent formulation in the osmotic delivery system if describedly back-diffusion is not controlled.Can regulate the rate of release of active agent formulation by the geometry of regulating flow channel 206, as described below.
The convective flow of activating agent by flow channel 206 is by the surfactant concentration decision in the active agent formulation in the container of the pump rate of osmotic delivery system and osmotic delivery system.Convective flow can be expressed as:
Qca=(Q)(Ca) (1)
Wherein Qca is the convective transport that is expressed as mg/ days activating agent (beneficial), and Q is expressed as cm 3The overall convective transport and the Ca of the active agent formulation in/sky are expressed as mg/cm 3The container of osmotic delivery system in active agent formulation in the concentration of activating agent.
The diffusional flow that activating agent leaves flow channel 206 is surfactant concentration and the shape of cross section of diffusibility and flow channel 206 and the function of length.Diffusional flow can be expressed as:
Q da = Dπ r 2 Δ C a L - - - ( 2 )
Wherein Qda is the diffusion transhipment that is expressed as mg/ days activating agent, and D is expressed as cm 2The diffusibility of passing through flow channel 206 in/sky, r is the effective internal diameter that is expressed as the flow channel 206 of cm, Δ Ca is expressed as mg/cm 3The osmotic delivery system container in the surfactant concentration of active agent formulation and the surfactant concentration in the fluid environment in delivery orifice 205 outsides of flow conditioner 200 poor, and L is (spiral) length that is expressed as the flow channel 206 of cm.
Usually, the surfactant concentration in the osmotic delivery system in the active agent formulation is more much bigger than the surfactant concentration in the fluid environment of using, and makes that described poor Δ Ca can be near the surfactant concentration Ca in the active agent formulation in the osmotic delivery system.Therefore:
Q da = Dπ r 2 C a L - - - ( 3 )
Usually the convective flow of the diffusion flux specific activity agent of expectation maintenance activating agent is much smaller.This can be expressed as follows:
Q da Q ca = D&pi; r 2 C a Q C a L = D&pi; r 2 QL < 1 - - - ( 4 )
Equation (4) expression relative diffusion flux reduces with the increase of volume flow velocity and path-length, increases with the increase of diffusibility and channel radius, and irrelevant with surfactant concentration.
Wherein flow channel 206 is can approximate representation as follows at the diffusion flux of the water at osmotic delivery system split shed place:
Q wd ( res ) = C o Q e ( - QL / D w A ) - - - ( 5 )
Wherein Co is expressed as mg/cm 3The CONCENTRATION DISTRIBUTION of water, Q is expressed as mg/ days mass velocity, L is the length that is expressed as the flow channel 206 of cm, Dw is expressed as cm 2The water in/sky is expressed as cm by the diffusibility and the A of material in the flow channel 206 2The cross-sectional area of flow channel 206.
The fluid dynamic pressure drop of crossing over delivery orifice can be calculated as follows:
&Delta;P = 8 QL&mu; &pi;r 4 - - - ( 6 )
Wherein Q is expressed as mg/ days mass velocity, and L is the helical flow passage length that is expressed as cm, and μ is the viscosity of preparation, and r is the effective internal diameter that is expressed as the flow channel of cm.
Fig. 3 represents to comprise the osmotic delivery system 300 of flow conditioner 200.Although osmotic delivery system 300 is expressed as the flow conditioner 200 with Fig. 2 A, apparent, any flow conditioner 200 shown in Fig. 2 A-2E can be used for osmotic delivery system 300.Osmotic delivery system 300 comprises container 302, and its size can be and makes and it can be implanted in vivo.Container 302 has open end 304,306.Flow conditioner 200 is inserted in the open end 304.Semipermeable plug 308 is inserted in the open end 306.
Semipermeable plug 308 is fluid flow films in the container 302 of the fluid environment that works therein from osmotic delivery system of control.Semipermeable plug 308 allows to enter container 302 from the fluid of fluid environment.Because the semipermeability character of semipermeable plug 308 is prevented from by semipermeable plug 308 flow containers 302 compositions in the container 302.Semipermeable plug 308 can partially or completely be inserted in the open end 306.In the previous case, semipermeable plug 308 can comprise the end portion 308a of expansion, and it works as the stopping element that the end with container 302 meshes.The outer surface 308b of semipermeable plug 308 can have projection or the burr 308c with inner surface 310 engagement of container 302, thereby is locked in semipermeable plug 308 on the container 302 and allows to form sealing between container 302 and semipermeable plug 308.Container 302 can also comprise undercutting, is used to accept the projection 308c on the semipermeable plug 308.The semipermeable materials that is used for semipermeable plug 308 is the material that can meet the shape of container 302 and can adhere to the inner surface 310 of container 302 when moistening.Typically, these materials are polymeric materials, and it can require to select according to pump rate and system configuration.The example of the semipermeable materials that is fit to includes but not limited to for example for example polyurethane and polyamide, polyphenylene ether-polyamide copolymer, thermoplastic copolyester or the like of hydroxyethyl meth acrylate (HEMA) and elastomeric material of plastifying cellulosic material, enhanced polymethyl methacrylate (PMMA).Common optimization polyurethane.
In container 302, limit two chambers 312,314.Piston that is for example slided by spacer 316 in chamber 312,314 or flexible membrane are separated, and described spacer is configured to cooperate container 302 in and produces sealing and contact and be used in container 302 longitudinally mobile or be out of shape.Preferably, spacer 316 is formed by the elastomeric material of impermeability.For example, spacer 316 can and can comprise the annular projection 316a that forms sealing with the inner surface 310 of container 302 for the sliding plunger made by the impermeability elastomeric material.Osmotic engine material 318 is arranged in the chamber 314 with semipermeable plug 308 adjacency, and active agent formulation is arranged in the chamber 312 with flow conditioner 200 adjacency.Spacer 316 makes active agent formulation 320 and the environment liquid separation that is allowed to enter by semipermeable plug 308 container 302, make in use, when steady-flow, active agent formulation 320 is to be discharged from by flow channel 206 by the suitable speed of the speed of semipermeable plug 308 inflow containers 302 from fluid environment with fluid.
Osmotic engine material 318 can be as directed tablet form.Can use one or more this tablets.Perhaps, osmotic engine material 318 can have other shape, quality, density and denseness.For example, osmotic engine material 318 can be powder or particle form.Osmotic engine material 318 can comprise osmopolymer (osmopolymer).Osmopolymer is to absorb aqueous fluid for example water and biological fluid and expand when sucking aqueous fluid or be expanded to poised state and keep signal portion and be absorbed fluidic hydrophilic polymer.Osmopolymers swell or be expanded to very high degree, being usually expressed as 2 to 50 times of volumes increases.Osmopolymer is can yes or no crosslinked.Preferred osmopolymer is slight cross-linked hydrophilic polymer, this crosslinked be by covalent bond or ionic bond or the residual crystal region after expanding forms.Osmopolymer can be plant, animal or synthetic source.Be suitable for the osmopolymer of osmotic engine material 318 or the example of hydrophilic polymer and include but not limited to that molecular weight is 30,000 to 5,000,000 poly-(hydroxy alkyl methacrylate); Molecular weight is 10,000 to 360,000 polyvinylpyrrolidone (PVP); Anionic and cationic hydrogel; Compound polyelectrolyte; The low acetate root is residual, be 200 to 30,000 polyvinyl alcohol with Biformyl, formaldehyde or glutaraldehyde cross-linking and the degree of polymerization, methylcellulose, crosslinked agar and the mixture of carboxymethyl cellulose; The mixture of hydroxypropyl emthylcellulose and sodium carboxymethyl cellulose; The mixture of Cellulose ethyl hydroxypropyl ether and sanlose; Sodium carboxymethyl cellulose; Carboxymethyl-cellulose potassium salt; By water-fast, the expandable copolymer of water that the dispersion of the finely divided copolymer of maleic anhydride and styrene, ethylene, propylene, butylene or isobutene. forms, every mole of maleic anhydride of every kind of copolymer has 0.001 to about 0.5 mole saturated cross-linking agent; The water swellable polymer of N-vinyl lactam; Polyethylene glycol oxide-polypropylene oxide gel; Polyoxybutylene-polyethylene block copolymer gel; Tragon; Carbopol gel; Polyester gel; Polyurea gel; The polyethers gel; Polyamide gels; Poly-cellulose gel; Poly-gummy gel (polygumgel); Absorb and the glassy hydrogel of adsorption and permeation and reduce the initial exsiccant hydrogel of the water of its vitrification point.Other example of osmopolymer comprises the polymer that forms hydrogel, for example: CARBOPOL
Figure G2007800187567D0010094828QIETU
, tart carboxyl polymer, a kind of polymerizing acrylic acid thing and crosslinked with polyene propyl group sucrose has another name called polyacrylic acid and carbopol, and molecular weight is 250,000 to 4,000,000; CYNAMER Polyacrylamide; The expandable indenes of crosslinked water-maleic anhydride polymer; Molecular weight is 80,000 to 200,000 GOOD-RITE
Figure G2007800187567D00112
Polyacrylic acid; Molecular weight is 100,000 to 5,000,000 and more high-molecular weight POLYOX
Figure G2007800187567D00113
Polyethylene oxide polymer; Starch graft copolymer; The AQUA KEEPS that forms by the glucose unit of condensation Acrylate polymer polysaccharide, for example crosslinked polysaccharide (polygluran) of diester; Or the like.Except osmopolymer or replace osmopolymer, osmotic engine material 318 can also comprise penetrating agent (osmagent).Penetrating agent comprises the inorganic and organic compound that shows the osmotic pressure gradient of striding semipermeable wall with respect to external fluid.Osmagents imbibe fluid in osmosis system, thereby utilize fluid to promote preparation, be used to send and pass through flow conditioner.Penetrating agent has another name called osmotically active chemical compound or solute.The example that can be used for the penetrating agent of osmotic engine material 318 comprises magnesium sulfate, magnesium chloride, sodium chloride, potassium sulfate, sodium sulfate, lithium sulfate, potassium hydrogen phosphate, mannitol, carbamide, inositol, Magnesium succinate, tartaric acid, carbohydrate for example cottonseed sugar (raffmose), sucrose, glucose, lactose, sorbitol and composition thereof.
Active agent formulation 320 can comprise one or more activating agents. activating agent can be the material of any physiology or pharmacological activity, particularly becomes known for being delivered to those of human body or animal body, for example medicine, vitamin, nutrient etc.Can include but not limited to act on infectious disease by the activating agent that flow conditioner 200 usefulness osmotic delivery system 300 are sent, chronic pain, diabetes, peripheral nervous, adrenoreceptor, cholinoceptor, skeletal muscle, cardiovascular system, smooth muscle, blood circulation, the synapse position, the neural effector bonding station, endocrine and hormone system, immune system, reproductive system, skeletal system, autocrine system, digestion and Excretory system, histamine system and central nervous system.The reagent that is fit to can be selected from for example synthetic analogues of protein, enzyme, hormone, polynucleotide, nucleoprotein, polysaccharide, glycoprotein, lipoprotein, polypeptide, steroidal, analgesic, local anesthetic, antibiotic, antiinflammatory usefulness corticosteroid, eye medicinal and these materials.Preferred activating agent comprises macromole (protein and peptide) and highly effective activating agent.Activating agent can be used as number of chemical and physical form exists, for example solid, liquid and slurry.Except one or more activating agents, preparation 320 can randomly comprise pharmaceutically acceptable carrier and/or other composition, for example antioxidant, stabilizing agent, buffer agent and penetration enhancers.
The material that is used for container 302 should be fully hard, do not change its size or shape so that stand the expansion of osmotic engine material 318.In addition, described material should guarantee under can be in the implantation process not suffered stress of container 302 or owing to seepage, crack under the stress of the pressure that produces in the operating process, break or be out of shape.Container 302 can be formed by inert, biocompatible, natural or synthetic material known in the art.The material of container 302 can be or not be biological erodible.Biological erodible material is partly dissolved at least, degrades in the fluid environment of its application or otherwise corrosion.Preferably, the material of container 302 is not biological erodible.Usually, the material of preferred container 302 is to be applicable to human those that implant.Preferably, the material right and wrong of container 302 are infiltrative, and particularly the preparation stability in container 302 is to the fluid environment of using when responsive.The example that is suitable for the material of container 302 comprises non-reactive polymer or biocompatible metals or alloy.The example that is used for the non-reactive polymer of container 302 includes but not limited to for example acrylonitrile-butadiene-styrene terpolymer of acrylonitrile polymer; Halogenated polymer is politef, polychlorotrifluoroethylene, tetrafluoroethene and hexafluoropropylene copolymer for example; Polyimides; Polysulfones; Merlon; Polyethylene; Polypropylene; Polrvinyl chloride-acrylic copolymer; Merlon-acrylonitrile-butadiene-styrene (ABS); And polystyrene.The example of the metallic alloy of container includes but not limited to rustless steel, titanium, platinum, tantalum, gold and their alloy, and the rustless steel of gold-plated ferroalloy, platinized ferroalloy, cochrome and titanium nitride coating.Use and wherein chemosensitive application in the body of preparation to implantation position for the decisive application of size, high payload capability, long duration, preferred container 302 is by titanium or have greater than the titanium alloy of 60% (usually greater than 85%) titanium and make.
Can select the diameter of flow conditioner 200, make flow conditioner 200 can be press fit in the open end 304 of container 302.Also might on the inner surface 310 of the outer surface 220 of shell 202 and container 302, comprise for example screw thread of feature, be used for respect to the fixing flow conditioner 200 of container 302.
Following examples are used to illustrate the present invention, should not be seen as restriction the present invention, unless explanation is arranged herein in addition.
Be used for the treatment of for example following assembled of osmotic delivery system of the interferon-ω of hepatitis C (IFN-ω) illustrated in fig. 3 comprising: (i) make and have at its end the container of undercutting by implanting the level titanium alloy, the osmotic engine material that (ii) comprises two cylindrical tablet, each tablet mainly comprises the sodium chloride salt with cellulose and polyvidone binding agent, (iii) piston, (iv) make and have the semipermeable plug of the maintenance burr that cooperates with undercutting in the container by polyurethane, (the flow conditioner that v) has the spiral type inner flow passage of D shape cross section, diameter 0.25mm, helix length is 35mm and the (suspension preparation that vi) comprises the granular preparation that is suspended in the IFN-ω in the non-water vehicle.
Suspension preparation with the vessel filling 150 μ L of above-mentioned several osmotic delivery system.The semipermeable plug ends of osmotic delivery system is placed the cuvette that is full of phosphate buffer (PBS), the flow modulator ends of osmotic delivery system is placed the cuvette that is full of moisture release medium.System is stored or insulation at 5 ℃ and 30 ℃ respectively.At specific time point, the solution that release medium can be removed and more renewed.Use reversed phase high-performance liquid chromatography (RP-HPLC) that the release medium of sampling is analyzed active agent content.The external accumulative total of IFN-ω that Fig. 4 was illustrated in June discharges.
The present invention can provide following advantage.Two-piece flow modulator makes the design of flow conditioner have motility and allows the manufacturability of flow conditioner.Shell and container are not whole, and make it possible to check before being inserted into flow conditioner in the container passage of flow conditioner.Two-piece flow modulator makes that the other mechanical force to passage minimizes in the process that flow conditioner is inserted in the container.Two-piece flow modulator allows to optimize by the passage on change inner core or the mobile insert motility of flow channel size in the shared trocar sheath of maintenance.
Although described embodiment with reference to limited embodiment, those skilled in the art should be appreciated that after understanding the present invention, can design other embodiment and do not break away from scope of the present invention disclosed herein.Therefore, scope of the present invention is only by the claim restriction of enclosing.

Claims (17)

1. be used for the implantable osmotic delivery system of active agent formulation, comprise:
The container of making by impermeable material;
First Room that comprises the osmotic engine material in container;
Second Room that comprises active agent formulation in container;
Be arranged in the container and the spacer that can move therein, described spacer limits first Room that comprises the osmotic engine material and second Room that comprises active agent formulation;
Be arranged on container first end, with the semipermeable plug of the first Room adjacency; With
Be arranged on container second end, with the flow conditioner of the second Room adjacency, described flow conditioner comprises:
Be positioned at the shell in the opening of second end of container of osmotic delivery system, described shell comprises inner surface;
Be inserted into the inner core in the described shell, described inner core comprises outer surface; With
The helical form flow channel that limits between the outer surface of the inner surface of described shell and inner core, described flow channel is suitable for the container delivery of active agent formulation from osmotic delivery system.
2. the implantable osmotic delivery system of claim 1, wherein flow channel is formed on the outer surface of the inner core that cooperates with the inner surface of shell.
3. the implantable osmotic delivery system of claim 1, wherein flow channel is formed on the inner surface of the shell that cooperates with the outer surface of inner core.
4. the implantable osmotic delivery system of claim 1 comprises the mobile insert that is arranged between shell and the inner core in addition, wherein forms flow channel in described mobile insert.
5. the implantable osmotic delivery system of claim 4, wherein shell, inner core and mobile insert are formed by inert material.
6. the implantable osmotic delivery system of claim 5, wherein inert material is nonmetallic materials.
7. the implantable osmotic delivery system of claim 1, wherein shell and inner core are formed by inert material.
8. the implantable osmotic delivery system of claim 7, wherein inert material is nonmetallic materials.
9. the implantable osmotic delivery system of claim 8, wherein said material is polyether-ether-ketone, polyaryletheretherketone, ultra-high molecular weight polyethylene, fluorizated ethylene-propylene, polymethylpentene or liquid crystal polymer.
10. the implantable osmotic delivery system of claim 1, wherein body seal meshes described inner core.
11. the implantable osmotic delivery system of claim 1, wherein said inner core comprise outside shoulder, described shell comprises inboard shoulder, and wherein said outside shoulder and the engagement of inboard shoulder are to prevent that in use inner core is discharged from shell.
12. the implantable osmotic delivery system of claim 1, wherein the length of flow channel is 10 to 50mm.
13. the implantable osmotic delivery system of claim 1, wherein the effective cross-section diameter of flow channel is 0.1 to 0.5mm.
14. the implantable osmotic delivery system of claim 1, wherein flow conditioner is press fit in second end of container.
15. each implantable osmotic delivery system of claim 1-14, wherein active agent formulation is selected from interferon-ω.
16. each implantable osmotic delivery system of claim 1-14, the material of wherein said container is selected from titanium or titanium alloy.
17. each implantable osmotic delivery system of claim 1-14, wherein said spacer is piston slidably.
CN2007800187567A 2006-05-30 2007-05-30 Two-piece, internal-channel osmotic delivery system flow modulator Active CN101453982B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80945106P 2006-05-30 2006-05-30
US60/809,451 2006-05-30
PCT/US2007/069990 WO2007140416A2 (en) 2006-05-30 2007-05-30 Two-piece, internal-channel osmotic delivery system flow modulator

Publications (2)

Publication Number Publication Date
CN101453982A CN101453982A (en) 2009-06-10
CN101453982B true CN101453982B (en) 2011-05-04

Family

ID=38617914

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800187567A Active CN101453982B (en) 2006-05-30 2007-05-30 Two-piece, internal-channel osmotic delivery system flow modulator

Country Status (16)

Country Link
US (8) US8052996B2 (en)
EP (1) EP2020990B1 (en)
JP (1) JP5143131B2 (en)
KR (1) KR101106510B1 (en)
CN (1) CN101453982B (en)
AT (1) ATE481963T1 (en)
AU (1) AU2007266475B2 (en)
CA (1) CA2651855C (en)
DE (1) DE602007009377D1 (en)
DK (1) DK2020990T3 (en)
ES (1) ES2351527T3 (en)
HK (1) HK1129203A1 (en)
IL (1) IL194746A (en)
MX (1) MX2008014870A (en)
NZ (1) NZ572003A (en)
WO (1) WO2007140416A2 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY125870A (en) * 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system flow modulator apparatus and method
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
JP4248236B2 (en) * 2000-11-29 2009-04-02 デュレクト コーポレイション Device and method for controlling delivery from a drug delivery device
KR20050026402A (en) * 2002-06-17 2005-03-15 알자 코포레이션 Osmotic delivery system with early zero order push power engine comprising an osmotic agent dispersed in the fluid vehicle
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CA2520610A1 (en) * 2003-03-31 2004-10-21 Alza Corporation Osmotic pump with means for dissipating internal pressure
TW200509999A (en) * 2003-03-31 2005-03-16 Alza Corp Osmotic delivery system and method for decreasing start-up times for osmotic delivery systems
US7407499B2 (en) * 2003-10-31 2008-08-05 Intarcia Therapeutics, Inc. Osmotic pump with self-retaining, fast-start membrane plug
WO2005046639A2 (en) * 2003-11-06 2005-05-26 Alza Corporation Modular imbibition rate reducer for use with implantable osmotic pump
EP1877077A2 (en) * 2005-02-03 2008-01-16 Intarcia Therapeutics, Inc. An implantable interferon-containing device
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US7959938B2 (en) * 2005-03-15 2011-06-14 Intarcia Therapeutics, Inc. Polyoxaester suspending vehicles for use with implantable delivery systems
JP5143131B2 (en) 2006-05-30 2013-02-13 インターシア セラピューティクス,インコーポレイティド Two-piece internal channel flow modulator for osmotic delivery system
PL2359808T3 (en) * 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotic delivery systems and piston assemblies
CA2683610C (en) 2007-04-23 2013-01-08 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
DK2240155T3 (en) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Devices, formulations and methods for the delivery of several beneficial agents
CN102281865B (en) * 2008-10-15 2017-04-05 精达制药公司 Highly enriched drug particles, preparation, suspensoid and its application
BRPI1006755A2 (en) * 2009-04-07 2019-03-26 Koninl Philips Electronics Nv drug delivery device
KR101823699B1 (en) 2009-09-28 2018-01-30 인타르시아 세라퓨틱스 인코포레이티드 Rapid establishment and/or termination of substantial steady-state drug delivery
US9017310B2 (en) 2009-10-08 2015-04-28 Palo Alto Research Center Incorporated Transmucosal drug delivery device and method including microneedles
US8882748B2 (en) 2009-10-08 2014-11-11 Palo Alto Research Center Incorporated Transmucosal drug delivery device and method including chemical permeation enhancers
US9014799B2 (en) 2009-10-08 2015-04-21 Palo Alto Research Center Incorporated Transmucosal drug delivery device and method including electrically-actuated permeation enhancement
US20110301555A1 (en) * 2010-06-03 2011-12-08 Gonzalez-Zugasti Javier P Porous matrix drug core for lacrimal insert device
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
KR101248035B1 (en) 2011-08-25 2013-04-09 강성삼 Safty brake system for automatic transmission car
US20130090633A1 (en) * 2011-10-07 2013-04-11 University Of Southern California Osmotic patch pump
US9046085B2 (en) * 2012-03-14 2015-06-02 Eden Medical, Inc. Miniature pumps
US20140088345A1 (en) * 2012-09-27 2014-03-27 Palo Alto Research Center Incorporated Single channel, multiple drug delivery device and methods
US9005108B2 (en) * 2012-09-27 2015-04-14 Palo Alto Research Center Incorporated Multiple reservoir drug delivery device and methods
US9999720B2 (en) 2012-09-27 2018-06-19 Palo Alto Research Center Incorporated Drug reconstitution and delivery device and methods
WO2014102741A2 (en) * 2012-12-28 2014-07-03 University Of The Witwatersrand, Johannesburg Pharmaceutical dosage form
US9744341B2 (en) 2013-01-15 2017-08-29 Palo Alto Research Center Incorporated Devices and methods for intraluminal retention and drug delivery
US9297083B2 (en) 2013-12-16 2016-03-29 Palo Alto Research Center Incorporated Electrolytic gas generating devices, actuators, and methods
WO2015116646A1 (en) * 2014-01-28 2015-08-06 Mccoy Enterprises, Llc Collagen permeated medical implants
US10278675B2 (en) 2014-07-31 2019-05-07 Palo Alto Research Center Incorporated Implantable estrus detection devices, systems, and methods
US9801660B2 (en) 2014-07-31 2017-10-31 Palo Alto Research Center Incorporated Implantable fluid delivery devices, systems, and methods
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US9903503B2 (en) * 2014-11-26 2018-02-27 B/E Aerospace, Inc. Aircraft water heating tank air vent valve
MX2017015504A (en) 2015-06-03 2018-05-15 Intarcia Therapeutics Inc Implant placement and removal systems.
WO2017079467A1 (en) 2015-11-05 2017-05-11 The General Hospital Corporation Intrathecal delivery of nucleic acid sequences encoding abcd1 for treatment of adrenomyeloneuropathy
AU2017268161B2 (en) 2016-05-16 2020-03-12 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
US10406336B2 (en) 2016-08-03 2019-09-10 Neil S. Davey Adjustable rate drug delivery implantable device
WO2018075901A1 (en) 2016-10-20 2018-04-26 Peptron, Inc. Methods of delivering a neuroprotective polypeptide to the central nervous system
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
EP3592376A1 (en) 2017-03-08 2020-01-15 Intarcia Therapeutics, Inc Apparatus and methods for administration of a nauseogenic compound from a drug delivery device
USD933219S1 (en) 2018-07-13 2021-10-12 Intarcia Therapeutics, Inc. Implant removal tool and assembly
CN113195524A (en) 2018-10-11 2021-07-30 因塔西亚治疗公司 Human amylin analog polypeptides and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524305B1 (en) * 1997-07-25 2003-02-25 Alza Corporation Osmotic delivery system flow modulator apparatus and method

Family Cites Families (509)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR640907A (en) 1927-06-25 1928-07-24 Automatic flow limiter
US2168437A (en) 1935-04-10 1939-08-08 Kenneth O Buercklin Injection device
US2110208A (en) 1937-02-12 1938-03-08 U S Standard Products Company Antigen preparations
US3025991A (en) 1960-05-23 1962-03-20 Carron Products Co Bottle stopper
GB1049104A (en) 1963-05-11 1966-11-23 Prodotti Antibiotici Spa Pharmaceutical compositions for oral or parenteral administration comprising tetracycline antibiotics
US3122162A (en) 1963-06-20 1964-02-25 Asa D Sands Flow control device
US3632768A (en) 1969-10-02 1972-01-04 Upjohn Co Therapeutic composition and method for treating infections with actinospectacin
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US4034756A (en) 1971-01-13 1977-07-12 Alza Corporation Osmotically driven fluid dispenser
US3732865A (en) 1971-01-13 1973-05-15 Alza Corp Osmotic dispenser
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
BE795516A (en) 1972-02-17 1973-08-16 Ciba Geigy PREPARATIONS OF OILY AND INJECTABLE PEPTIDES AND PROCESS FOR THEIR PREPARATION
US3797492A (en) 1972-12-27 1974-03-19 Alza Corp Device for dispensing product with directional guidance member
US3995632A (en) 1973-05-04 1976-12-07 Alza Corporation Osmotic dispenser
DE2528516A1 (en) 1974-07-05 1976-01-22 Sandoz Ag NEW GALENIC PREPARATION
US3987790A (en) 1975-10-01 1976-10-26 Alza Corporation Osmotically driven fluid dispenser
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4078060A (en) 1976-05-10 1978-03-07 Richardson-Merrell Inc. Method of inducing an estrogenic response
US4111202A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4111201A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for delivering selected beneficial agents having varying degrees of solubility
US4243030A (en) 1978-08-18 1981-01-06 Massachusetts Institute Of Technology Implantable programmed microinfusion apparatus
US4305927A (en) 1979-02-05 1981-12-15 Alza Corporation Method for the management of intraocular pressure
US4373527B1 (en) 1979-04-27 1995-06-27 Univ Johns Hopkins Implantable programmable medication infusion system
US4310516A (en) 1980-02-01 1982-01-12 Block Drug Company Inc. Cosmetic and pharmaceutical vehicle thickened with solid emulsifier
AU546785B2 (en) 1980-07-23 1985-09-19 Commonwealth Of Australia, The Open-loop controlled infusion of diabetics
US4350271A (en) 1980-08-22 1982-09-21 Alza Corporation Water absorbing fluid dispenser
US4376118A (en) 1980-10-06 1983-03-08 Miles Laboratories, Inc. Stable nonaqueous solution of tetracycline salt
US4340054A (en) 1980-12-29 1982-07-20 Alza Corporation Dispenser for delivering fluids and solids
US4455145A (en) 1981-07-10 1984-06-19 Alza Corporation Dispensing device with internal drive
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
EP0079143A3 (en) 1981-10-20 1984-11-21 Adnovum Ag Pseudoplastic gel transfer
EP0080879B1 (en) 1981-11-28 1986-10-01 Sunstar Kabushiki Kaisha Pharmaceutical composition containing interferon in stable state
US5004689A (en) 1982-02-22 1991-04-02 Biogen, Massachusetts DNA sequences, recombinant DNA molecules and processes for producing human gamma interferon-like polypeptides in high yields
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4455143A (en) 1982-03-22 1984-06-19 Alza Corporation Osmotic device for dispensing two different medications
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
DE3220116A1 (en) 1982-05-28 1983-12-01 Dr. Karl Thomae Gmbh, 7950 Biberach MICROBIOLOGICALLY MANUFACTURED (ALPHA) AND SS INTERFERONES, DNA SEQUENCES CODING FOR THESE INTERFERONES, MICROORGANISMS CONTAINING THIS GENETIC INFORMATION, AND METHOD FOR THE PRODUCTION THEREOF
US4753651A (en) 1982-08-30 1988-06-28 Alza Corporation Self-driven pump
US4966843A (en) 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
US4552561A (en) 1982-12-23 1985-11-12 Alza Corporation Body mounted pump housing and pump assembly employing the same
US4673405A (en) 1983-03-04 1987-06-16 Alza Corporation Osmotic system with instant drug availability
US4639244A (en) 1983-05-03 1987-01-27 Nabil I. Rizk Implantable electrophoretic pump for ionic drugs and associated methods
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
DE3320583A1 (en) 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach NEW GALENIC PREPARATION FORMS OF ORAL ANTIDIABETICS AND METHOD FOR THE PRODUCTION THEREOF
JPS6058915A (en) 1983-09-12 1985-04-05 Fujisawa Pharmaceut Co Ltd Lipid microcapsule preparation containing medicament
US4594108A (en) 1983-09-19 1986-06-10 The Dow Chemical Company Highly pseudoplastic polymer solutions
US5385738A (en) 1983-10-14 1995-01-31 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release injection
US4855238A (en) 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
MX9203641A (en) 1983-12-16 1992-07-01 Genentech Inc RECOMBINANT GAMMA INTERFERONS THAT HAVE IMPROVED STABILITY AND BIOTECHNOLOGICAL METHODS FOR THEIR OBTAINING.
US4851228A (en) 1984-06-20 1989-07-25 Merck & Co., Inc. Multiparticulate controlled porosity osmotic
US5120832A (en) 1984-08-27 1992-06-09 Genentech, Inc. Distinct family of human leukocyte interferons
US5231176A (en) 1984-08-27 1993-07-27 Genentech, Inc. Distinct family DNA encoding of human leukocyte interferons
US4927687A (en) 1984-10-01 1990-05-22 Biotek, Inc. Sustained release transdermal drug delivery composition
US5411951A (en) 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
FI90990C (en) 1984-12-18 1994-04-25 Boehringer Ingelheim Int Recombinant DNA molecule, transformed host organism, and method for producing interferon
US4655462A (en) 1985-01-07 1987-04-07 Peter J. Balsells Canted coiled spring and seal
JPS61189230A (en) 1985-02-19 1986-08-22 Nippon Kayaku Co Ltd Etoposide preparation
US4609374A (en) 1985-04-22 1986-09-02 Alza Corporation Osmotic device comprising means for governing initial time of agent release therefrom
DE3685996T2 (en) 1985-06-11 1993-01-14 Ciba Geigy Ag HYBRID INTERFERONE.
US4845196A (en) 1985-06-24 1989-07-04 G. D. Searle & Co. Modified interferon gammas
US4847079A (en) 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
DE3607835A1 (en) 1986-03-10 1987-09-24 Boehringer Ingelheim Int HYBRID INTERFERONS, THEIR USE AS MEDICINAL PRODUCTS AND AS INTERMEDIATE PRODUCTS FOR THE PRODUCTION OF ANTIBODIES AND THE USE THEREOF AND METHOD FOR THEIR PRODUCTION
US4865845A (en) 1986-03-21 1989-09-12 Alza Corporation Release rate adjustment of osmotic or diffusional delivery devices
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US4755180A (en) 1986-06-16 1988-07-05 Alza Corporation Dosage form comprising solubility regulating member
DE3636123A1 (en) 1986-10-23 1988-05-05 Rentschler Arzneimittel ORAL ADMINISTRATIVE PREPARATIONS CONTAINING SINGLE DOSE FROM 10 TO 240 MG DIHYDROPYRIDINE
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
ZA878295B (en) 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
DE3642096A1 (en) 1986-12-10 1988-06-16 Boehringer Ingelheim Int HORSE (GAMMA) INTERFERON
US5371089A (en) 1987-02-26 1994-12-06 Senetek, Plc Method and composition for ameliorating the adverse effects of aging
US5278151A (en) 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
JPH0720866B2 (en) 1987-05-15 1995-03-08 三生製薬株式会社 Transdermal preparation containing eperisone or tolperisone or their salts
US4940465A (en) 1987-05-27 1990-07-10 Felix Theeuwes Dispenser comprising displaceable matrix with solid state properties
US4892778A (en) 1987-05-27 1990-01-09 Alza Corporation Juxtaposed laminated arrangement
US4874388A (en) 1987-06-25 1989-10-17 Alza Corporation Multi-layer delivery system
US5938654A (en) 1987-06-25 1999-08-17 Alza Corporation Osmotic device for delayed delivery of agent
US5023088A (en) 1987-06-25 1991-06-11 Alza Corporation Multi-unit delivery system
US4915949A (en) 1987-07-13 1990-04-10 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
US4915954A (en) 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
US5756450A (en) 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
US4886668A (en) 1987-09-24 1989-12-12 Merck & Co., Inc. Multiparticulate controlled porosity osmotic pump
US4917895A (en) 1987-11-02 1990-04-17 Alza Corporation Transdermal drug delivery device
JPH0740268Y2 (en) * 1988-04-07 1995-09-13 株式会社東海理化電機製作所 Sliding contact switch
US4964204A (en) 1988-04-25 1990-10-23 Peter J. Balsells Method for making a garter-type axially-resilient coil spring
US4961253A (en) 1988-04-25 1990-10-09 Peter J. Balsells Manufacturing method for canted-coil spring with turn angle and seal
US5160122A (en) 1990-03-20 1992-11-03 Peter J. Balsells Coil spring with an elastomer having a hollow coil cross section
US4907788A (en) 1988-04-25 1990-03-13 Peter J. Balsells Dual concentric canted-coil spring apparatus
US4974821A (en) 1988-04-25 1990-12-04 Peter J. Balsells Canted-coil spring with major axis radial loading
US5108078A (en) 1988-04-25 1992-04-28 Peter J. Balsells Canted-coil spring loaded while in a cavity
US4915366A (en) 1988-04-25 1990-04-10 Peter J. Balsells Outside back angle canted coil spring
US4876781A (en) 1988-04-25 1989-10-31 Peter J. Balsells Method of making a garter-type axially resilient coiled spring
US5079388A (en) 1989-12-01 1992-01-07 Peter J. Balsells Gasket for sealing electromagnetic waves
US4893795A (en) 1988-08-15 1990-01-16 Peter J. Balsells Radially loaded canted coiled spring with turn angle
US5072070A (en) 1989-12-01 1991-12-10 Peter J. Balsells Device for sealing electromagnetic waves
US4934666A (en) 1988-04-25 1990-06-19 Peter J. Balsells Coiled spring electromagnetic shielding gasket
EP0339544B1 (en) 1988-04-25 1993-09-22 Peter J. Balsells Garter spring with canted back angle located on outside diameter
US5117066A (en) 1988-04-25 1992-05-26 Peter J. Balsells Retaining and locking electromagnetic gasket
US4826144A (en) 1988-04-25 1989-05-02 Peter J. Balsells Inside back angle canted coil spring
US5203849A (en) 1990-03-20 1993-04-20 Balsells Peter J Canted coil spring in length filled with an elastomer
US4830344A (en) 1988-04-25 1989-05-16 Peter J. Balsells Canted-coil spring with turn angle and seal
US5006346A (en) 1988-04-28 1991-04-09 Alza Corporation Delivery system
US5024842A (en) 1988-04-28 1991-06-18 Alza Corporation Annealed coats
US5160743A (en) 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
US4931285A (en) 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
JP2794022B2 (en) 1988-11-11 1998-09-03 三生製薬株式会社 Transdermal preparation containing bunazosin or its salts
US5728088A (en) 1988-12-13 1998-03-17 Alza Corporation Osmotic system for delivery of fluid-sensitive somatotropins to bovine animals
US5057318A (en) 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5059423A (en) 1988-12-13 1991-10-22 Alza Corporation Delivery system comprising biocompatible beneficial agent formulation
US5110596A (en) 1988-12-13 1992-05-05 Alza Corporation Delivery system comprising means for delivering agent to livestock
US5034229A (en) 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
US5234424A (en) 1988-12-28 1993-08-10 Alza Corporation Osmotically driven syringe
US4969884A (en) 1988-12-28 1990-11-13 Alza Corporation Osmotically driven syringe
US4976966A (en) 1988-12-29 1990-12-11 Alza Corporation Delayed release osmotically driven fluid dispenser
US5288479A (en) 1989-01-17 1994-02-22 Sterling Drug, Inc. Extrudable elastic oral pharmaceutical gel compositions and metered dose dispensers containing them and method of making and method of use thereof
US5705363A (en) 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
US5906816A (en) 1995-03-16 1999-05-25 University Of Florida Method for treatment of autoimmune diseases
US5219572A (en) 1989-03-17 1993-06-15 Pitman-Moore, Inc. Controlled release delivery device for macromolecular proteins
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5126142A (en) 1989-07-18 1992-06-30 Alza Corporation Dispenser comprising ionophore
US5112614A (en) 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US5290558A (en) 1989-09-21 1994-03-01 Osteotech, Inc. Flowable demineralized bone powder composition and its use in bone repair
SE465950B (en) 1989-10-23 1991-11-25 Medinvent Sa Combination of an aggregate particle size, crystalline or freeze-dried drug with a pseudoplastic gel for preparation of an injectable preparation as well as a process for its preparation
DE69003805T2 (en) 1989-11-13 1994-05-19 Becton Dickinson France STORAGE CONTAINER FOR A COMPONENT OF A MEDICINAL SOLUTION.
JPH03236317A (en) 1989-12-06 1991-10-22 Sansei Seiyaku Kk Dopamine derivative-containing percutaneous
US5030216A (en) 1989-12-15 1991-07-09 Alza Corporation Osmotically driven syringe
US5733572A (en) 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5213809A (en) 1990-01-24 1993-05-25 Alza Corporation Delivery system comprising means for controlling internal pressure
US5223266A (en) 1990-01-24 1993-06-29 Alza Corporation Long-term delivery device with early startup
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5122128A (en) 1990-03-15 1992-06-16 Alza Corporation Orifice insert for a ruminal bolus
US5120306A (en) 1990-03-21 1992-06-09 Gosselin Leon F Direct delivery of anti-inflammatories to the proximal small bowel
US5207752A (en) 1990-03-30 1993-05-04 Alza Corporation Iontophoretic drug delivery system with two-stage delivery profile
US5324280A (en) 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5091188A (en) 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5290271A (en) 1990-05-14 1994-03-01 Jernberg Gary R Surgical implant and method for controlled release of chemotherapeutic agents
US5374620A (en) 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
US5180591A (en) 1990-07-11 1993-01-19 Alza Corporation Delivery device with a protective sleeve
US5234693A (en) 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234692A (en) 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234695A (en) 1990-07-24 1993-08-10 Eastman Kodak Company Water dispersible vitamin E composition
US5300302A (en) 1990-10-04 1994-04-05 Nestec S.A. Pharmaceutical composition in gel form in a dispensing package
US5529914A (en) 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
US5151093A (en) 1990-10-29 1992-09-29 Alza Corporation Osmotically driven syringe with programmable agent delivery
IT1243390B (en) 1990-11-22 1994-06-10 Vectorpharma Int PHARMACEUTICAL COMPOSITIONS IN THE FORM OF PARTICLES SUITABLE FOR THE CONTROLLED RELEASE OF PHARMACOLOGICALLY ACTIVE SUBSTANCES AND PROCEDURE FOR THEIR PREPARATION.
US5161806A (en) 1990-12-17 1992-11-10 Peter J. Balsells Spring-loaded, hollow, elliptical ring seal
GB9027422D0 (en) 1990-12-18 1991-02-06 Scras Osmotically driven infusion device
MX9200038A (en) 1991-01-09 1992-11-01 Alza Corp BIODEGRADABLE DEVICES AND COMPOSITIONS FOR THE RELEASE BY DIFFUSION OF AGENTS.
US5443459A (en) 1991-01-30 1995-08-22 Alza Corporation Osmotic device for delayed delivery of agent
US5861166A (en) 1991-03-12 1999-01-19 Alza Corporation Delivery device providing beneficial agent stability
US5113938A (en) 1991-05-07 1992-05-19 Clayton Charley H Whipstock
US5137727A (en) 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
EP0520119A1 (en) 1991-06-17 1992-12-30 Spirig Ag Pharmazeutische Präparate New oral diclofenac composition
US5252338A (en) 1991-06-27 1993-10-12 Alza Corporation Therapy delayed
US5190765A (en) 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
US5288214A (en) 1991-09-30 1994-02-22 Toshio Fukuda Micropump
YU87892A (en) 1991-10-01 1995-12-04 Eli Lilly And Company Lilly Corporate Center INJECTIBLE LONG TERM RELEASE FORMULATIONS AND PROCEDURES FOR THEIR OBTAINING AND USE
EP0607321A1 (en) 1991-10-10 1994-07-27 Alza Corporation Osmotic drug delivery devices with hydrophobic wall materials
US5318780A (en) 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
US5236707A (en) 1991-11-08 1993-08-17 Dallas Biotherapeutics, Inc. Stabilization of human interferon
AU3136293A (en) 1991-11-15 1993-06-15 Isp Investments Inc. Pharmaceutical tablet with pvp having an enhanced drug dissolution rate
DE4137649C2 (en) 1991-11-15 1997-11-20 Gerhard Dingler Component
US5200195A (en) 1991-12-06 1993-04-06 Alza Corporation Process for improving dosage form delivery kinetics
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5223265A (en) 1992-01-10 1993-06-29 Alza Corporation Osmotic device with delayed activation of drug delivery
US5676942A (en) 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
US5209746A (en) 1992-02-18 1993-05-11 Alza Corporation Osmotically driven delivery devices with pulsatile effect
US5456679A (en) 1992-02-18 1995-10-10 Alza Corporation Delivery devices with pulsatile effect
US5308348A (en) 1992-02-18 1994-05-03 Alza Corporation Delivery devices with pulsatile effect
US5573934A (en) 1992-04-20 1996-11-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
US5221278A (en) 1992-03-12 1993-06-22 Alza Corporation Osmotically driven delivery device with expandable orifice for pulsatile delivery effect
WO1993019739A1 (en) 1992-03-30 1993-10-14 Alza Corporation Viscous suspensions of controlled-release drug particles
AU3941793A (en) 1992-03-30 1993-11-08 Alza Corporation Additives for bioerodible polymers to regulate degradation
US6197346B1 (en) 1992-04-24 2001-03-06 Brown Universtiy Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
FR2690622B1 (en) 1992-04-29 1995-01-20 Chronotec Programmable ambulatory infusion pump system.
US5314685A (en) 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
US5711968A (en) 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
US5413672A (en) 1992-07-22 1995-05-09 Ngk Insulators, Ltd. Method of etching sendust and method of pattern-etching sendust and chromium films
US5512293A (en) 1992-07-23 1996-04-30 Alza Corporation Oral sustained release drug delivery device
US5609885A (en) 1992-09-15 1997-03-11 Alza Corporation Osmotic membrane and delivery device
GB9223146D0 (en) 1992-11-05 1992-12-16 Scherer Corp R P Vented capsule
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
SE9203594D0 (en) 1992-11-30 1992-11-30 Christer Nystroem DISPERSA SYSTEM MEDICINAL PRODUCT
US5368588A (en) 1993-02-26 1994-11-29 Bettinger; David S. Parenteral fluid medication reservoir pump
WO1994021262A1 (en) 1993-03-17 1994-09-29 Alza Corporation Device for the transdermal administration of alprazolam
US5514110A (en) 1993-03-22 1996-05-07 Teh; Eutiquio L. Automatic flow control device
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
NZ250844A (en) 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
NZ247516A (en) 1993-04-28 1995-02-24 Bernard Charles Sherman Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5639477A (en) 1993-06-23 1997-06-17 Alza Corporation Ruminal drug delivery device
JPH08512054A (en) 1993-06-25 1996-12-17 アルザ・コーポレーション Inclusion of poly-N-vinylamide in transdermal system
US5498255A (en) 1993-08-17 1996-03-12 Alza Corporation Osmotic device for protracted pulsatile delivery of agent
JP2700141B2 (en) 1993-09-17 1998-01-19 富士化学工業株式会社 Calcium hydrogen phosphate, its production method and excipient using the same
NZ275615A (en) 1993-09-29 1996-11-26 Alza Corp Oxybutynin composition containing monoglyceride and lactate ester as permeability enhancers; device for transdermal administration of oxybutynin
US5540665A (en) 1994-01-31 1996-07-30 Alza Corporation Gas driven dispensing device and gas generating engine therefor
AU691249B2 (en) 1994-02-04 1998-05-14 Lipocore Holding Ab Bilayer preparations
US5697975A (en) 1994-02-09 1997-12-16 The University Of Iowa Research Foundation Human cerebral cortex neural prosthetic for tinnitus
US5458888A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
EP0741577B1 (en) 1994-03-07 2002-11-06 IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY &amp; MEDICINE The use of interferon subtype alpha 8 in the preparation of medicaments to treat viral infections of the liver
ZA953078B (en) 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
WO1995034285A1 (en) 1994-06-13 1995-12-21 Alza Corporation Dosage form for administering drug in liquid formulation
NL9401150A (en) 1994-07-12 1996-02-01 Nederland Ptt Method for presenting on a receiving side a first number of video signals originating from a transmitting side, as well as a system, as well as a transmitter, as well as a network, and also a receiver.
ES2153485T3 (en) 1994-07-13 2001-03-01 Alza Corp COMPOSITION AND PROCEDURE THAT INCREASES THE PERCUTANEOUS DIFFUSION BY ELECTROTRANSPORT OF A SUBSTANCE.
US5633011A (en) 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5595759A (en) 1994-11-10 1997-01-21 Alza Corporation Process for providing therapeutic composition
DK0788351T3 (en) 1994-11-10 2003-05-26 Univ Kentucky Res Found Implantable, refillable device for speed-controlled drug delivery directly to an internal part of the body
FR2731150B1 (en) 1995-03-03 1997-04-18 Oreal USE OF AMPHIPHILIC COMPOUNDS AS A THICKENING AGENT FOR NON-AQUEOUS MEDIA
US5595751A (en) 1995-03-06 1997-01-21 Ethicon, Inc. Absorbable polyoxaesters containing amines and/or amido groups
US5648088A (en) 1995-03-06 1997-07-15 Ethicon, Inc. Blends of absorbable polyoxaesters containing amines and/or amide groups
US6100346A (en) 1995-03-06 2000-08-08 Ethicon, Inc. Copolymers of polyoxaamides
US5859150A (en) 1995-03-06 1999-01-12 Ethicon, Inc. Prepolymers of absorbable polyoxaesters
US5464929A (en) 1995-03-06 1995-11-07 Ethicon, Inc. Absorbable polyoxaesters
US6147168A (en) 1995-03-06 2000-11-14 Ethicon, Inc. Copolymers of absorbable polyoxaesters
US5962023A (en) 1995-03-06 1999-10-05 Ethicon, Inc. Hydrogels containing absorbable polyoxaamides
US5607687A (en) 1995-03-06 1997-03-04 Ethicon, Inc. Polymer blends containing absorbable polyoxaesters
US5700583A (en) 1995-03-06 1997-12-23 Ethicon, Inc. Hydrogels of absorbable polyoxaesters containing amines or amido groups
US6403655B1 (en) 1995-03-06 2002-06-11 Ethicon, Inc. Method of preventing adhesions with absorbable polyoxaesters
US5618552A (en) 1995-03-06 1997-04-08 Ethicon, Inc. Absorbable polyoxaesters
US5698213A (en) 1995-03-06 1997-12-16 Ethicon, Inc. Hydrogels of absorbable polyoxaesters
US5844017A (en) 1995-03-06 1998-12-01 Ethicon, Inc. Prepolymers of absorbable polyoxaesters containing amines and/or amido groups
US5597579A (en) 1995-03-06 1997-01-28 Ethicon, Inc. Blends of absorbable polyoxaamides
US5736159A (en) 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
CN1170596C (en) 1995-05-02 2004-10-13 大正制药株式会社 Composition for oral administration
US5939286A (en) 1995-05-10 1999-08-17 University Of Florida Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them
US5882676A (en) 1995-05-26 1999-03-16 Alza Corporation Skin permeation enhancer compositions using acyl lactylates
WO1996039142A1 (en) 1995-06-06 1996-12-12 F. Hoffmann-La Roche Ag Pharmaceutical composition comprising a proteinase inhibitor and a monoglyceride
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US5690952A (en) 1995-06-07 1997-11-25 Judy A. Magruder et al. Implantable system for delivery of fluid-sensitive agents to animals
IL122432A (en) 1995-06-07 2000-07-16 Cygnus Therapeutic Systems Transdermal patch for preventing ovulation
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US6572879B1 (en) 1995-06-07 2003-06-03 Alza Corporation Formulations for transdermal delivery of pergolide
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US6129761A (en) 1995-06-07 2000-10-10 Reprogenesis, Inc. Injectable hydrogel compositions
US5782396A (en) 1995-08-28 1998-07-21 United States Surgical Corporation Surgical stapler
US5906830A (en) 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
GB9521125D0 (en) 1995-10-16 1995-12-20 Unilever Plc Cosmetic composition
US5766620A (en) 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
GB9521805D0 (en) 1995-10-25 1996-01-03 Cortecs Ltd Solubilisation methods
PT771817E (en) 1995-10-30 2003-06-30 Oleoyl Estrone Developments S OLEATE ESTERS OF ESTROGEN FOR THE TREATMENT OF OBESITY AND / OR EXCESS OF WEIGHT
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
AUPN723395A0 (en) 1995-12-19 1996-01-18 Macnaught Medical Pty Limited Lubrication methods
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
US6132420A (en) 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
US6156331A (en) 1996-02-02 2000-12-05 Alza Corporation Sustained delivery of an active agent using an implantable system
AU2526497A (en) 1996-02-02 1997-08-22 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
US6261584B1 (en) 1996-02-02 2001-07-17 Alza Corporation Sustained delivery of an active agent using an implantable system
SK284136B6 (en) 1996-02-02 2004-09-08 Alza Corporation Implantable device for delivering leuprolide to a fluid medium
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
NZ330973A (en) 1996-03-08 2000-03-27 Zeneca Ltd Azolobenzazepine derivatives as neurologically active agents
JP2000506865A (en) 1996-03-14 2000-06-06 ジ イミューン リスポンス コーポレイション Targeted delivery of genes encoding interferons
US5703200A (en) 1996-03-15 1997-12-30 Ethicon, Inc. Absorbable copolymers and blends of 6,6-dialkyl-1,4-dioxepan-2-one and its cyclic dimer
US5660858A (en) 1996-04-03 1997-08-26 Research Triangle Pharmaceuticals Cyclosporin emulsions
US6204022B1 (en) 1996-04-12 2001-03-20 Pepgen Corporation And University Of Florida Low-toxicity human interferon-alpha analogs
US6074673A (en) 1996-04-22 2000-06-13 Guillen; Manuel Slow-release, self-absorbing, drug delivery system
US5976109A (en) 1996-04-30 1999-11-02 Medtronic, Inc. Apparatus for drug infusion implanted within a living body
EP0928136B1 (en) 1996-06-05 2003-10-22 Ashmont Holdings Limited Injectable compositions
US6767887B1 (en) 1996-06-05 2004-07-27 Roche Diagnostics Gmbh Exendin analogues, processes for their preparation and medicaments containing them
DE29610419U1 (en) 1996-06-14 1996-10-24 Filtertek, S.A., Plailly Gravity infusion device for medical infusions
GB9613858D0 (en) 1996-07-02 1996-09-04 Cortecs Ltd Hydrophobic preparations
EP0909175B1 (en) 1996-07-03 2003-06-04 Alza Corporation Non-aqueous protic peptide formulations
US5916582A (en) 1996-07-03 1999-06-29 Alza Corporation Aqueous formulations of peptides
US5932547A (en) 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
ATE322272T1 (en) 1996-07-15 2006-04-15 Alza Corp NEW FORMULATIONS FOR TRANSDERMAL ADMINISTRATION OF FLUOXETINE
AR008789A1 (en) 1996-07-31 2000-02-23 Bayer Corp PIRIDINES AND SUBSTITUTED BIPHENYLS
DK0966297T4 (en) 1996-08-08 2013-03-18 Amylin Pharmaceuticals Llc Regulation of gastrointestinal motility
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
IN184589B (en) 1996-10-16 2000-09-09 Alza Corp
ES2191834T3 (en) 1996-10-24 2003-09-16 Alza Corp AGENTS THAT FACILITATE THE PERMEATION AND DESTINATIONS FOR COMPOSITIONS, DEVICES AND PROCEDURES OF TRANSDERMAL CONTRIBUTION OF DRUGS.
US5817129A (en) 1996-10-31 1998-10-06 Ethicon, Inc. Process and apparatus for coating surgical sutures
UA65549C2 (en) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight
DE19646392A1 (en) 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Preparation for use in the oral cavity with a layer containing pressure-sensitive adhesive, pharmaceuticals or cosmetics for dosed delivery
US5928666A (en) 1996-11-12 1999-07-27 Cygnus Inc. Crystalline form of estradiol and pharmaceutical formulations comprising same
DK1066081T3 (en) 1996-11-15 2003-12-01 Alza Corp Osmotic delivery system and method to improve the commissioning and implementation of osmotic delivery systems
CA2591581C (en) 1996-12-20 2013-01-29 Alza Corporation Gel composition and methods
GB9626513D0 (en) 1996-12-20 1997-02-05 Bioglan Ireland R & D Ltd A pharmaceutical composition
ATE304864T1 (en) 1997-01-07 2005-10-15 Amylin Pharmaceuticals Inc USE OF EXEDINES AND THEIR ANTAGONISTS TO REDUCE FOOD INTAKE
JP2001511128A (en) 1997-01-28 2001-08-07 ファルマシア・アンド・アップジョン・カンパニー Lyophilized product of lipid complex of water-insoluble porphyrin
ZA981610B (en) 1997-03-24 1999-08-26 Alza Corp Self adjustable exit port.
US5874388A (en) 1997-04-02 1999-02-23 Dow Corning Corporation Lubricant composition for disc brake caliper pin and a disc brake asembly containing the lubricant
US6127520A (en) 1997-04-15 2000-10-03 Regents Of The University Of Michigan Compositions and methods for the inhibition of neurotransmitter uptake of synaptic vesicles
EP0975331A1 (en) 1997-04-17 2000-02-02 Dumex-Alpharma A/S A novel bioadhesive drug delivery system based on liquid crystals
CA2288306A1 (en) * 1997-04-28 1998-11-05 Rhone-Poulenc Rorer S.A. Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
US20020039594A1 (en) 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
US6663899B2 (en) 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
SI9700186B (en) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Novel pharmaceutical preparation with controlled release of active healing substances
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
US6172046B1 (en) 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
PL195212B1 (en) 1997-09-29 2007-08-31 Nektar Therapeutics Perforated microparticles and method of using them
JPH11100353A (en) 1997-09-29 1999-04-13 Esupo Kk Refined and deodorized liquid ester wax and its composition
US6133429A (en) 1997-10-03 2000-10-17 Becton Dickinson And Company Chromophores useful for the preparation of novel tandem conjugates
ES2297902T5 (en) 1997-11-14 2013-07-09 Amylin Pharmaceuticals, Inc. Novel agonist compounds from exendina
US6299869B1 (en) 1997-12-08 2001-10-09 Genentech, Inc. Human interferon-epsilon: a type I interferon
US6368612B1 (en) 1997-12-12 2002-04-09 Biohybrid Technologies Llc Devices for cloaking transplanted cells
JP4215188B2 (en) 1997-12-22 2009-01-28 インターシア セラピューティクス,インコーポレイティド Rate-regulating membranes for devices that regulate drug delivery
CA2316976C (en) 1997-12-29 2009-02-17 Alza Corporation Osmotic delivery system with membrane plug retention mechanism
JP4188560B2 (en) 1997-12-29 2008-11-26 インターシア セラピューティクス,インコーポレイティド Transplant device for subcutaneous implant
DE69836149T2 (en) 1997-12-30 2007-08-16 Alza Corp., Mountain View ADMINISTRATIVE SYSTEM FOR ACTIVE SUBSTANCES USING A MEMBRANE PAD
US20040024068A1 (en) 1998-01-23 2004-02-05 Trustees Of Tufts College Antimicrobial compounds
IT1298575B1 (en) 1998-02-06 2000-01-12 Vectorpharma Int PHARMACEUTICAL COMPOSITIONS IN THE FORM OF NANOPARTICLES INCLUDING LIPID SUBSTANCES AND ANTIPHILIC SUBSTANCES AND RELATED PROCESS OF
US6017545A (en) 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
AU759058C (en) 1998-02-13 2005-09-15 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
US6224577B1 (en) 1998-03-02 2001-05-01 Medrad, Inc. Syringes and plungers for use therein
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6183461B1 (en) 1998-03-11 2001-02-06 Situs Corporation Method for delivering a medication
EP0984039A4 (en) 1998-03-12 2002-01-02 Daicel Chem Lactone-containing resin composition, molded object thereof, and film
US6029361A (en) 1998-03-25 2000-02-29 Ultratech Stepper, Inc. Air-guage nozzle probe structure for microlithographic image focusing
US6074660A (en) 1998-04-20 2000-06-13 Ethicon, Inc. Absorbable polyoxaesters containing amines and/ or amido groups
TW586944B (en) 1998-05-29 2004-05-11 Sumitomo Pharma Controlled release agent having a multi-layer structure
CA2334872C (en) 1998-06-12 2014-08-19 Bionebraska, Inc. Use of exendin-4 to treat impaired glucose tolerance
US7390637B2 (en) 1998-07-21 2008-06-24 Human Genome Sciences, Inc. Keratinocyte derived interferon
US6472512B1 (en) 1998-07-21 2002-10-29 Human Genome Sciences, Inc. Keratinocyte derived interferon
US6720407B1 (en) 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
US6551613B1 (en) 1998-09-08 2003-04-22 Alza Corporation Dosage form comprising therapeutic formulation
US6174547B1 (en) 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
EP1112060B1 (en) 1998-09-09 2005-12-07 ALZA Corporation Dosage form comprising liquid formulation
US6248112B1 (en) 1998-09-30 2001-06-19 C. R. Bard, Inc. Implant delivery system
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
EP1126827A2 (en) 1998-11-02 2001-08-29 Alza Corporation Controlled delivery of active agents
WO2000029206A1 (en) 1998-11-13 2000-05-25 Sensor Technologies Inc. Monodisperse preparations useful with implanted devices
US20030060425A1 (en) 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
BR9915961A (en) 1998-12-07 2001-08-21 Sod Conseils Rech Applic Glp-1 analogs
WO2000035419A2 (en) 1998-12-17 2000-06-22 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
CN1158068C (en) 1998-12-23 2004-07-21 安姆根有限公司 Polyol/oil suspensions for the sustained release of proteins
EP1140144A4 (en) 1998-12-31 2002-10-30 Viragen Inc Composition of highly purified natural mixtures of type i interferon derived from leukocytes and methods
ES2196918T3 (en) 1998-12-31 2003-12-16 Alza Corp OSMOTIC SUPPLY SYSTEM EQUIPPED WITH PISTON WITH SPACE ECONOMY.
US6433144B1 (en) 1999-01-12 2002-08-13 Viragen, Inc. Compositions of highly-purified natural mixtures of type I Interferon derived from leukocytes and methods
WO2000040273A2 (en) 1999-01-08 2000-07-13 Vical Incorporated Treatment of viral diseases using an interferon omega expressing polynucleotide
US6703225B1 (en) 1999-01-12 2004-03-09 Sumitomo Pharmaceuticals Company, Limited Interferon-α
NZ512657A (en) 1999-01-14 2004-01-30 Amylin Pharmaceuticals Inc Glucagon suppression
US7399489B2 (en) 1999-01-14 2008-07-15 Amylin Pharmaceuticals, Inc. Exendin analog formulations
ES2244416T5 (en) 1999-01-14 2020-01-03 Amylin Pharmaceuticals Llc Novel formulations of exendon agonists and their administration methods
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
KR100858856B1 (en) 1999-02-08 2008-09-17 인타르시아 세라퓨틱스 인코포레이티드 Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US6451974B1 (en) 1999-03-17 2002-09-17 Novo Nordisk A/S Method of acylating peptides and novel acylating agents
US6835194B2 (en) 1999-03-18 2004-12-28 Durect Corporation Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
US6541021B1 (en) 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
BR0009840A (en) 1999-04-19 2002-01-08 Schering Corp Combination therapy for hcv, containing ribavirin in combination with antioxidants
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
DK1180121T3 (en) 1999-05-17 2004-03-01 Conjuchem Inc Long-acting insulinotropic peptides
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
JP2003501404A (en) 1999-06-04 2003-01-14 デルルックス ファーマシューティカル コーポレイション Preparation comprising dehydrated particles of drug and method of preparing same
US20030059376A1 (en) 1999-06-04 2003-03-27 Libbey Miles A. Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
NZ530701A (en) 1999-06-04 2005-09-30 Alza Corp Implantable gel compositions comprising compressed particles including the active agent in a bioerodible gel
US6833256B1 (en) 1999-06-22 2004-12-21 University Of Maryland Interferon tau mutants and methods for making them
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US6436091B1 (en) 1999-11-16 2002-08-20 Microsolutions, Inc. Methods and implantable devices and systems for long term delivery of a pharmaceutical agent
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
AU2092701A (en) 1999-12-17 2001-06-25 Durect Corporation Devices and methods in intracerebrospinal delivery of morphine-6-glucuronide
WO2001045675A2 (en) 1999-12-21 2001-06-28 Alza Corporation Valve for osmotic devices
US6283949B1 (en) 1999-12-27 2001-09-04 Advanced Cardiovascular Systems, Inc. Refillable implantable drug delivery pump
US6572890B2 (en) 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
US6472060B1 (en) 2000-01-19 2002-10-29 Seco Tools Ab Coated body with nanocrystalline CVD coating for enhanced edge toughness and reduced friction
US6844321B2 (en) 2000-01-31 2005-01-18 Novo Nordisk A/S Crystallization of a GLP-1 analogue
US6465425B1 (en) 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US6471688B1 (en) 2000-02-15 2002-10-29 Microsolutions, Inc. Osmotic pump drug delivery systems and methods
US6464688B1 (en) 2000-02-15 2002-10-15 Microsolutions, Inc. Osmotic pump delivery system with flexible drug compartment
WO2001068112A2 (en) 2000-03-14 2001-09-20 Goeke Burkhard Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
US20030211974A1 (en) 2000-03-21 2003-11-13 Brodbeck Kevin J. Gel composition and methods
AU2001259111B2 (en) 2000-04-19 2005-12-08 Durect Corporation Sustained release formulations comprising growth hormone
CA2407074A1 (en) 2000-04-21 2001-11-01 Jukka Hartikka Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
JP2001357075A (en) 2000-04-27 2001-12-26 El-Con System Co Ltd System and method for calculating quantity of materials while utilizing two-dimensional cad interface
DE60134403D1 (en) 2000-05-19 2008-07-24 Amylin Pharmaceuticals Inc TREATMENT OF ACUTE CORONARY SYNDROME WITH GLP-1
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
BR0111562A (en) 2000-06-16 2003-04-15 Lilly Co Eli Glucagon-like peptide 1 analogs
US6479065B2 (en) 2000-08-10 2002-11-12 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
CA2423431A1 (en) 2000-10-06 2002-04-11 Durect Corporation Devices and methods for management of inflammation
CA2427194A1 (en) 2000-11-03 2002-05-10 Biomedicines, Inc. Method for short-term and long-term drug dosimetry
EP1335704A2 (en) 2000-11-16 2003-08-20 Durect Corporation Implant dosage form and use thereof for the delivery of a cholesterol lowering agent
JP4248236B2 (en) 2000-11-29 2009-04-02 デュレクト コーポレイション Device and method for controlling delivery from a drug delivery device
US20020165286A1 (en) 2000-12-08 2002-11-07 Hanne Hedeman Dermal anti-inflammatory composition
EP1351984A2 (en) 2000-12-13 2003-10-15 Eli Lilly And Company Amidated glucagon-like peptide-1
CA2431173A1 (en) 2000-12-13 2002-06-20 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
JP2004515533A (en) 2000-12-14 2004-05-27 アミリン・ファーマシューティカルズ,インコーポレイテッド Peptide YY and peptide YY agonist for treating metabolic disorders
IN188924B (en) 2001-03-01 2002-11-23 Bharat Serums & Vaccines Ltd
CA2440387A1 (en) 2001-03-23 2002-10-03 Durect Corporation Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space
US6632217B2 (en) 2001-04-19 2003-10-14 Microsolutions, Inc. Implantable osmotic pump
JP2005506956A (en) 2001-06-01 2005-03-10 イーライ・リリー・アンド・カンパニー Long-acting GLP-1 formulation
US6514517B2 (en) 2001-06-20 2003-02-04 Ethicon, Inc. Antimicrobial coatings for medical devices
US7318931B2 (en) 2001-06-21 2008-01-15 Genentech, Inc. Sustained release formulation
EP1401503B1 (en) 2001-06-22 2007-05-09 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug and a solubility-enhancing polymer
US7163688B2 (en) 2001-06-22 2007-01-16 Alza Corporation Osmotic implant with membrane and membrane retention means
US20030138403A1 (en) 2001-06-29 2003-07-24 Maxygen Aps Interferon formulations
AU2002317599B2 (en) 2001-07-31 2008-04-03 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GLP-1 exendin-4 peptide analogs and uses thereof
EP1432730A4 (en) 2001-08-23 2006-10-11 Lilly Co Eli Glucagon-like peptide-1 analogs
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
WO2003024357A2 (en) 2001-09-14 2003-03-27 Martin Francis J Microfabricated nanopore device for sustained release of therapeutic agent
ATE443513T1 (en) 2001-09-17 2009-10-15 Durect Corp DEVICE AND METHOD FOR ACCURATE DELIVERY OF AN ACTIVE SUBSTANCE
AU2002332054B2 (en) 2001-09-24 2007-11-08 Imperial Innovations Limited Modification of feeding behavior
US7041646B2 (en) 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
CA2460690A1 (en) 2001-10-05 2003-04-17 Intermune, Inc. Method of treating hepatitis virus infection with a multiphasic interferon delivery profile
WO2003063573A2 (en) 2001-11-09 2003-08-07 Intarcia Therapeutics, Inc. Method for treating diseases with omega interferon
DE60232987D1 (en) 2001-11-14 2009-08-27 Durect Corp INJECTABLE DEPOT COMPOSITIONS
EP1446100B1 (en) 2001-11-14 2011-05-04 Durect Corporation Injectable depot compositions and uses thereof
JP2005519873A (en) 2001-11-14 2005-07-07 アルザ・コーポレーション Catheter injectable depot compositions and their use
US20030108608A1 (en) 2001-12-12 2003-06-12 Erik Laridon Thermoplastic articles comprising silver-containing antimicrobials and high amounts of carboxylic acid salts for increased surface-available silver
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
US8058233B2 (en) 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
US7105489B2 (en) 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
GB2386066A (en) 2002-02-28 2003-09-10 Norbrook Lab Ltd Long-acting parasiticidal composition with improved bioavailability comprising a salicylanilide, a further anti-parasitic compound & a polymeric species
GB0204722D0 (en) 2002-02-28 2002-04-17 Norferm Da Method
EP1572915A4 (en) 2002-04-11 2011-01-05 Medimmune Vaccines Inc Preservation of bioactive materials by spray drying
KR20050026402A (en) 2002-06-17 2005-03-15 알자 코포레이션 Osmotic delivery system with early zero order push power engine comprising an osmotic agent dispersed in the fluid vehicle
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
ATE376854T1 (en) 2002-06-26 2007-11-15 Alza Corp MINIMALLY FORGIVE VOLUME EFFICIENT PISTON FOR OSMOTIC DRUG DELIVERY SYSTEMS
US7177526B2 (en) 2002-06-28 2007-02-13 Intel Corporation System and method for improving audio during post-production of video recordings
IL166418A0 (en) 2002-07-31 2006-01-15 Alza Corp Injectable depot compositions and uses thereof
US8501215B2 (en) 2002-07-31 2013-08-06 Guohua Chen Injectable multimodal polymer depot compositions and uses thereof
US20080260838A1 (en) 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
JP2006506386A (en) 2002-10-22 2006-02-23 ワラタ ファーマシューティカルズ, インコーポレイテッド Diabetes treatment
BR0315304A (en) 2002-11-06 2005-08-16 Alza Corp Depot formulations for controlled release
US6969702B2 (en) 2002-11-20 2005-11-29 Neuronova Ab Compounds and methods for increasing neurogenesis
US7014636B2 (en) * 2002-11-21 2006-03-21 Alza Corporation Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel
US7790681B2 (en) 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20040224903A1 (en) 2002-12-19 2004-11-11 Stephen Berry Stable, non-aqueous, single-phase gels and formulations thereof for delivery from an implantable device
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
JP2004238392A (en) 2003-01-14 2004-08-26 Nipro Corp Stabilized proteinic preparation
CA2520610A1 (en) 2003-03-31 2004-10-21 Alza Corporation Osmotic pump with means for dissipating internal pressure
TW200509999A (en) 2003-03-31 2005-03-16 Alza Corp Osmotic delivery system and method for decreasing start-up times for osmotic delivery systems
US20050008661A1 (en) 2003-03-31 2005-01-13 Fereira Pamela J. Non-aqueous single phase vehicles and formulations utilizing such vehicles
EP1982772A1 (en) 2003-05-16 2008-10-22 Cinvention Ag Bio-compatible coated medical implants
US20050079202A1 (en) 2003-05-30 2005-04-14 Guohua Chen Implantable elastomeric depot compositions and uses thereof
WO2005000222A2 (en) 2003-05-30 2005-01-06 Amylin Pharmaceuticals, Inc. Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
ATE541582T1 (en) 2003-06-03 2012-02-15 Novo Nordisk As STABILIZED PHARMACEUTICAL GLP-1 PEPTIDE COMPOSITIONS
US8491571B2 (en) * 2003-06-12 2013-07-23 Cordis Corporation Orifice device having multiple channels with varying flow rates for drug delivery
US7205409B2 (en) 2003-09-04 2007-04-17 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
AU2004277980A1 (en) 2003-09-30 2005-04-14 Alza Corporation Osmotically driven active agent delivery device providing an ascending release profile
US7407499B2 (en) 2003-10-31 2008-08-05 Intarcia Therapeutics, Inc. Osmotic pump with self-retaining, fast-start membrane plug
WO2005046639A2 (en) 2003-11-06 2005-05-26 Alza Corporation Modular imbibition rate reducer for use with implantable osmotic pump
US20050118206A1 (en) 2003-11-14 2005-06-02 Luk Andrew S. Surfactant-based gel as an injectable, sustained drug delivery vehicle
US20050106214A1 (en) 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
US20050281879A1 (en) 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles
US7780973B2 (en) 2003-12-15 2010-08-24 Ethicon Endo-Surgery, Inc. Method and device for minimally invasive implantation of biomaterial
US20050175701A1 (en) 2004-02-10 2005-08-11 Alza Corporation Capillary moderator for osmotic delivery system
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
AU2005211755B2 (en) 2004-02-11 2012-03-15 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
MXPA06011924A (en) 2004-04-15 2007-06-11 Alkermes Inc Polymer-based sustained release device.
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
US20050266087A1 (en) 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
US20090042781A1 (en) 2004-06-28 2009-02-12 Novo Nordisk A/S Methods for Treating Diabetes
US7772182B2 (en) 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
GB2434189B (en) 2004-08-18 2009-04-01 Waters Investments Ltd Defined leak path for high pressure seal
US8268791B2 (en) 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US7442682B2 (en) 2004-10-19 2008-10-28 Nitto Denko Corporation Transepithelial delivery of peptides with incretin hormone activities
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
WO2006052608A2 (en) 2004-11-01 2006-05-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
US20060141040A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
US20060142234A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
EP1841448A2 (en) 2004-12-30 2007-10-10 Diakine Therapeutics, Inc. Pharmaceutical compositions and methods for restoring beta-cell mass and function
AU2006208131A1 (en) 2005-01-25 2006-08-03 Microchips, Inc. Control of drug release by transient modification of local microenvironments
US20060216242A1 (en) 2005-02-03 2006-09-28 Rohloff Catherine M Suspending vehicles and pharmaceutical suspensions for drug dosage forms
EP1877077A2 (en) 2005-02-03 2008-01-16 Intarcia Therapeutics, Inc. An implantable interferon-containing device
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
US7959938B2 (en) 2005-03-15 2011-06-14 Intarcia Therapeutics, Inc. Polyoxaester suspending vehicles for use with implantable delivery systems
EA013121B1 (en) 2005-03-31 2010-02-26 Амилин Фармасьютикалз, Инк. Amylin and amylin agonists for treating psychiatric diseases and disorders
ATE509634T1 (en) 2005-04-08 2011-06-15 Amylin Pharmaceuticals Inc PHARMACEUTICAL FORMULATIONS CONTAINING INCRETIN PEPTIDE AND APROTIC-POLAR SOLVENT
JP2008536881A (en) 2005-04-21 2008-09-11 ガストロテック・ファルマ・アクティーゼルスカブ Pharmaceutical formulation of GLP-1 molecule and antiemetic
US7699833B2 (en) 2005-05-06 2010-04-20 Moberg Sheldon B Pump assembly and method for infusion device
US20060280795A1 (en) 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
AU2006279680B2 (en) 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
US8389472B2 (en) 2005-08-19 2013-03-05 Amylin Pharmaceuticals, Llc Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
HUE064811T2 (en) 2005-08-19 2024-04-28 Amylin Pharmaceuticals Llc Exendin for use in treating diabetes and reducing body weight
JP2009514900A (en) 2005-11-04 2009-04-09 スミスクライン・ビーチャム・コーポレイション Administration method of hypoglycemic agent
US8293869B2 (en) 2005-12-16 2012-10-23 Nektar Therapeutics Polymer conjugates of GLP-1
CA2634016A1 (en) 2005-12-16 2007-07-05 Amylin Pharmaceuticals, Inc. Compositions and methods for treating obesity and related metabolic disorders
WO2007084460A2 (en) 2006-01-18 2007-07-26 Qps, Llc Pharmaceutical compositions with enhanced stability
CN101432025B (en) 2006-03-21 2012-04-04 安米林药品公司 Peptide-peptidase inhibitor conjugates and methods of using same
AU2007247137A1 (en) 2006-05-02 2007-11-15 Actogenix N.V. Microbial intestinal delivery of obesity related peptides
WO2007133778A2 (en) 2006-05-12 2007-11-22 Amylin Pharmaceuticals, Inc. Methods to restore glycemic control
JP5143131B2 (en) * 2006-05-30 2013-02-13 インターシア セラピューティクス,インコーポレイティド Two-piece internal channel flow modulator for osmotic delivery system
GB0613196D0 (en) 2006-07-03 2006-08-09 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
US8501693B2 (en) 2006-08-04 2013-08-06 Amylin Pharmaceuticals, Llc Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen
PL2359808T3 (en) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotic delivery systems and piston assemblies
WO2008061355A1 (en) 2006-11-24 2008-05-29 Matregen Corp. Glp-1 depot systems, and methods of manufacture and uses thereof
TWI428346B (en) 2006-12-13 2014-03-01 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
WO2008092084A2 (en) 2007-01-26 2008-07-31 Centocor, Inc. Injectable non-aqueous suspension with high concentration of therapeutic agent
CA2683610C (en) 2007-04-23 2013-01-08 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
US8236760B2 (en) 2007-04-27 2012-08-07 Cedars-Sinsai Medical Center Use of GLP-1 receptor agonists for the treatment of short bowel syndrome
US20090202481A1 (en) 2008-02-08 2009-08-13 Qps Llc Composition for Sustained Release Delivery of Proteins or Peptides
DK2240155T3 (en) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Devices, formulations and methods for the delivery of several beneficial agents
AU2009214632B2 (en) 2008-02-14 2015-02-19 Reshape Lifesciences, Inc. Treatment of excess weight by neural downregulation in combination with compositions
US20110046071A1 (en) 2008-03-05 2011-02-24 Tel Hashomer Medical Research Infrastructure And Services Ltd. GLP-1 Receptor Agonists And Related Active Pharmaceutical Ingredients For Treatment Of Cancer
EP2343982B1 (en) 2008-09-17 2017-03-22 Chiasma Inc. Pharmaceutical compositions and related methods of delivery
CN102281865B (en) 2008-10-15 2017-04-05 精达制药公司 Highly enriched drug particles, preparation, suspensoid and its application
KR101823699B1 (en) 2009-09-28 2018-01-30 인타르시아 세라퓨틱스 인코포레이티드 Rapid establishment and/or termination of substantial steady-state drug delivery
AR079345A1 (en) 2009-12-22 2012-01-18 Lilly Co Eli OXINTOMODULINE PEPTIDAL ANALOG
WO2011156407A2 (en) 2010-06-09 2011-12-15 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonists to treat pancre-atitis
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524305B1 (en) * 1997-07-25 2003-02-25 Alza Corporation Osmotic delivery system flow modulator apparatus and method

Also Published As

Publication number Publication date
NZ572003A (en) 2010-07-30
US8367095B2 (en) 2013-02-05
US20130247376A1 (en) 2013-09-26
US8273365B2 (en) 2012-09-25
CN101453982A (en) 2009-06-10
HK1129203A1 (en) 2009-11-20
US20130138089A1 (en) 2013-05-30
US20170181964A1 (en) 2017-06-29
AU2007266475B2 (en) 2009-12-03
AU2007266475A1 (en) 2007-12-06
ATE481963T1 (en) 2010-10-15
IL194746A0 (en) 2009-09-22
CA2651855A1 (en) 2007-12-06
US20150231062A1 (en) 2015-08-20
CA2651855C (en) 2011-08-02
US8052996B2 (en) 2011-11-08
ES2351527T3 (en) 2011-02-07
KR101106510B1 (en) 2012-01-20
DK2020990T3 (en) 2010-12-13
WO2007140416A2 (en) 2007-12-06
US20120184945A1 (en) 2012-07-19
US8158150B2 (en) 2012-04-17
WO2007140416A3 (en) 2008-10-30
KR20090003342A (en) 2009-01-09
JP2009538717A (en) 2009-11-12
US9539200B2 (en) 2017-01-10
US20110301576A1 (en) 2011-12-08
EP2020990A2 (en) 2009-02-11
MX2008014870A (en) 2009-02-12
JP5143131B2 (en) 2013-02-13
US20120330282A1 (en) 2012-12-27
US8470353B2 (en) 2013-06-25
DE602007009377D1 (en) 2010-11-04
US8992962B2 (en) 2015-03-31
US20070281024A1 (en) 2007-12-06
EP2020990B1 (en) 2010-09-22
IL194746A (en) 2014-05-28

Similar Documents

Publication Publication Date Title
CN101453982B (en) Two-piece, internal-channel osmotic delivery system flow modulator
AU2002315374B2 (en) Osmotic implant with membrane and membrane retention means
US20080269726A1 (en) Osmotic pump with self-retaining, fast-start membrane plug
NO314223B1 (en) Osmotic system for delivering fluid-sensitive somatotropin to bovine animals
AU2012330960B2 (en) Osmotically active vaginal delivery system
KR20050120767A (en) Osmotic delivery system and method for decreasing start-up times for osmotic delivery systems

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1129203

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1129203

Country of ref document: HK